Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
Redx Pharma is pleased to be participating today at BioInfect, the major one day conference bringing together industry leaders to focus on the threat of antimicrobial resistance and the critical issues relating to the development of new anti-infectives.
Antimicrobial resistance (AMR) is an increasingly serious global public health issue that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. Redx is working in collaboration with the NHS to tackle AMR, and the Group's anti-infectives subsidiary has one of the biggest research teams in the UK, if not Europe, developing the next generation of antibiotics.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.